PharmaPoint: Prostate Cancer - Global Drug Forecast and Market Analysis to 2022
GlobalData's report "PharmaPoint: Prostate Cancer - Global Drug Forecast and Market Analysis to 2022", provides comprehensive information on prostate cancer therapeutics, highlighting the treatment guidelines and identifies and analyses the key trends shaping and driving the market. The report analyses the treatment usage patterns and provides insights into the competitive landscape and the emerging players expected to significantly alter the positions of the existing market leaders. Valuable insights into the pipeline products is included. The report quantifies the unmet need in the global market as well as in the individual markets such as the US and the top five countries in Europe, highlighting the opportunity for future players. This report is built using data and information sourced from proprietary databases, primary and secondary and in-house analysis by GlobalDatas team of industry experts.
Key Questions Answered
- How will the prostate cancer market size and composition change over the forecast period? How will the role of each therapeutic class change in the treatment of prostate cancer?
- What is the degree of unmet need among different segments of prostate cancer patients, and how will this change over the forecast period? How will pipeline drugs attempt to meet these needs?
- The two dominant therapies in the prostate cancer market will be J&Js Zytiga (abiraterone acetate) and Medivation/Astellas Xtandi (enzalutamide). Which will be the victor in each market, and why?
- What are the strengths and weaknesses of currently marketed and pipeline drugs, and how do they stack up against one another? Which will have the greatest commercial success?
- The launch of safe and orally administered therapies for mCRPC will drive growth in the market over the forecast period.
- New market entrants will increase competition in the mCRPC market and will decrease the level of unmet need.
- The release of Xtandi from Astellas/Medivation for refractory mCRPC patients, as well as the approval of both J&Js Zytiga and Xtandi for the chemotherapy-na